Statements (29)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:alsoKnownAs |
gptkb:zuranolone
|
| gptkbp:approvalYear |
2023
|
| gptkbp:ATCCode |
N06AX34
|
| gptkbp:brand |
gptkb:Zurzuvae
|
| gptkbp:CASNumber |
2254647-23-6
|
| gptkbp:chemicalFormula |
C22H29FN2O2
|
| gptkbp:clinicalTrialPhase |
Phase 3
|
| gptkbp:developedBy |
gptkb:Biogen
gptkb:Sage_Therapeutics |
| gptkbp:drugClass |
antidepressant
neuroactive steroid |
| gptkbp:FDAApprovedFor |
postpartum depression
|
| https://www.w3.org/2000/01/rdf-schema#label |
SAGE-217
|
| gptkbp:indication |
gptkb:major_depressive_disorder
postpartum depression |
| gptkbp:legalStatus |
prescription only
|
| gptkbp:mechanismOfAction |
GABA-A receptor positive allosteric modulator
|
| gptkbp:molecularWeight |
372.48 g/mol
|
| gptkbp:pregnancyCategory |
not recommended
|
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
diarrhea
dizziness fatigue urinary tract infection somnolence |
| gptkbp:UNII |
6X9OC3H4WW
|
| gptkbp:bfsParent |
gptkb:zuranolone
|
| gptkbp:bfsLayer |
7
|